Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Visual Outcomes of Central Retinal Artery Occlusion: Exploring Treatment Strategies Beyond the Conventional Time Window.
J Stroke Cerebrovasc Dis
January 2025
Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China; Department of Ophthalmology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, Republic of China. Electronic address:
Backgrounds/aims: Central retinal artery occlusion (CRAO) is a vision-devastating emergency. However, widely-acknowledged treatment consensus is lacking and prehospital delays commonly occur. Hence, we aimed to investigate the visual outcomes of conservative treatments (CT), local intra-arterial fibrinolysis (LIF) and hyperbaric oxygen (HBO) therapy for non-arteritic CRAO (NA-CRAO) patients beyond the conventional time window.
View Article and Find Full Text PDFA simple polydopamine-based platform for engineering extracellular vesicles with brain-targeting peptide and imaging probes to improve stroke outcome.
J Extracell Vesicles
January 2025
Shanghai Jiao Tong University Affiliated Sixth People's Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Extracellular vesicles (EVs) have shown great potential for treating various diseases. Translating EVs-based therapy from bench to bedside remains challenging due to inefficient delivery of EVs to the injured area and lack of techniques to visualize the entire targeting process. Here we developed a dopamine surface functionalization platform that facilitates easy and simultaneous conjugation of targeting peptide and multi-mode imaging probes to the surface of EVs.
View Article and Find Full Text PDFPhospholipid Nanoparticles: A Novel Colloid for Blood Volume Replacement, Reanimation, and Organ Protection in Hemorrhagic Shock.
Biomedicines
December 2024
Department of Surgery, School of Medicine, University of Missouri Kansas City, Kansas City, MO 64108, USA.
: Exsanguination is a leading cause of preventable death in military and civilian settings due to extensive blood loss and hemorrhagic shock, which trigger systemic effects such as impaired tissue perfusion, hypoxia, inflammation, and multi-organ dysfunction. Standard resuscitation restores blood volume but fails to address critical aspects of hemorrhagic shock, including inflammation, coagulopathy, and reperfusion injury. To address these limitations, novel phospholipid nanoparticle (PNP)-based resuscitative fluids, VBI-S and VBI-1, were developed to modulate nitric oxide (NO) levels, improving hemodynamic stability, tissue oxygenation, and reducing inflammatory injury.
View Article and Find Full Text PDFAnimal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies.
Asia Ocean J Nucl Med Biol
January 2025
Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, Tehran, Iran.
Article Synopsis
- Liver cancer is a major cause of cancer deaths, and using beta-emitting radionuclides in targeted treatments like Ho-hydroxyapatite (Ho-HA) is a promising approach.
- The study estimated radiation absorbed doses of Ho-HA in the liver and other tissues using specific calculation methods, revealing that over 84% of the dose concentrated in liver tissue.
- Ho-HA treatment allows for high doses to the tumor while minimizing exposure to healthy tissues, suggesting its potential effectiveness for liver cancer therapy.
Purpose: Tirofiban has emerged as an adjunct therapy for acute ischemic stroke (AIS) patients undergoing endovascular treatment (EVT). However, its benefits for AIS patients with intracranial atherosclerotic disease (ICAD) remains unclear. This meta-analysis evaluates its efficacy and safety in ICAD-related AIS patients undergoing EVT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!